Published in PLoS One on August 04, 2016
How mitochondria produce reactive oxygen species. Biochem J (2009) 13.03
AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer (2003) 8.88
EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol (2009) 4.45
Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell (2003) 3.92
Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem (2000) 3.12
Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem (1993) 2.69
A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest (1998) 2.16
Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res (2008) 1.76
Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem (1995) 1.69
The proto-oncogene c-Fos transcriptionally regulates VEGF production during peritoneal inflammation. Kidney Int (2013) 1.54
Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci U S A (1991) 1.53
Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci U S A (1997) 1.47
Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Liver Int (2008) 1.46
Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J Clin Invest (1993) 1.46
Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin Chem Lab Med (2003) 1.43
Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res (1996) 1.41
The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology (1997) 1.34
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A (2001) 1.31
A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature (1994) 1.31
Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology (1990) 1.25
Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology (2010) 1.21
Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol (2008) 1.18
Cytokine induction of NO synthase II in human DLD-1 cells: roles of the JAK-STAT, AP-1 and NF-kappaB-signaling pathways. Br J Pharmacol (1998) 1.13
Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes. Hepatology (2009) 1.12
Cholestatic liver disease: pathophysiology and therapeutic options. Liver (2002) 1.09
Cyclosporine A-induced oxidative stress in rat hepatocytes. J Pharmacol Exp Ther (1997) 1.08
Roles of cyclin D1 and related genes in growth inhibition, senescence and apoptosis. Apoptosis (1999) 1.07
Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation. Gastroenterology (2003) 1.05
Hydrogen peroxide decreases endothelial nitric oxide synthase promoter activity through the inhibition of AP-1 activity. Am J Physiol Lung Cell Mol Physiol (2008) 1.02
Hypoxia-induced upregulation of eNOS gene expression is redox-sensitive: a comparison between hypoxia and inhibitors of cell metabolism. J Cell Physiol (2001) 0.98
Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes. Am J Physiol Gastrointest Liver Physiol (2007) 0.98
TNF-alpha induces a decrease in eNOS promoter activity. Am J Physiol Lung Cell Mol Physiol (2003) 0.94
Nitric oxide in liver injury. Hepatology (1999) 0.94
Nuclear retinoid receptors and their mechanism of action. Vitam Horm (1994) 0.91
Transcriptional induction of endothelial nitric oxide gene by cyclosporine A. A role for activator protein-1. J Biol Chem (2000) 0.89
Curcumin and liver disease. Biofactors (2013) 0.88
Nordihydroguaiaretic acid increases endothelial nitric oxide synthase expression via the transcription factor AP-1. DNA Cell Biol (2007) 0.85
Role of AP1 element in the activation of human eNOS promoter by lysophosphatidylcholine. J Cell Biochem (2006) 0.83
Characterization of the human insulin-induced gene 2 (INSIG2) promoter: the role of Ets-binding motifs. J Biol Chem (2010) 0.83
GCDCA down-regulates gene expression by increasing Sp1 binding to the NOS-3 promoter in an oxidative stress dependent manner. Biochem Pharmacol (2015) 0.80
The human transcription factor AP-1 is a mediator of bile acid-induced liver cell apoptosis. Biochem Biophys Res Commun (2005) 0.80
Beneficial effect of quercetin on cholestatic liver injury. J Nutr Biochem (2014) 0.79
Mitochondrial-driven ubiquinone enhances extracellular calcium-dependent nitric oxide production and reduces glycochenodeoxycholic acid-induced cell death in hepatocytes. Chem Res Toxicol (2009) 0.78
Unexpected protection of glomerular mesangial cells from oxidant-triggered apoptosis by bioflavonoid quercetin. Am J Physiol (1997) 0.77